Hormone therapy for menopause: a complete, current guide
You read "hormone therapy" and your stomach tightens. Your mother was told it caused cancer. A headline two decades ago scared a whole generation away. So you have white-knuckled the hot flashes, the 3 a.m. wakeups, the dryness no one talks about, because the treatment sounded scarier than the symptoms. Here is what almost no one told you: the science moved, the official guidance moved, and in February 2026 the FDA itself moved. The fear you inherited is older than the evidence. Let's walk through what hormone therapy actually is, in plain language, as it stands right now.
The short version: Menopausal hormone therapy uses estrogen alone or estrogen with a progestogen. Systemic estrogen is the most effective treatment for hot flashes and night sweats, while systemic and local estrogen can relieve vaginal dryness. For most healthy, symptomatic women younger than 60 who are within 10 years of menopause onset, The Menopause Society says benefits generally outweigh risks. Suitability still depends on symptoms and medical history. 2, 5
- The two treatment types and the systemic and local routes
- Why a patch, pill, gel, or vaginal product can have a different risk profile
- What the February 2026 FDA label changes did and did not change
- How timing, symptoms, and medical history shape suitability
The route you take it matters as much as the dose
Why does the route matter beyond convenience? The Menopause Society says transdermal routes and lower doses may decrease the risk of venous thromboembolism and stroke. That is evidence for a clinician to weigh with dose, symptoms, and history, not a rule to self-apply. 2
The benefits are real, and so is the 2026 reset
On February 12, 2026, FDA approved changes for six menopausal hormone-therapy products, removing cardiovascular-disease, breast-cancer and probable-dementia risk statements from their boxed warnings. This did not remove all risk information or make every product suitable for everyone. Systemic estrogen-alone products retain the endometrial-cancer boxed warning. After estrogen-dependent breast cancer, ACOG recommends nonhormonal GSM care first. Selected low-dose vaginal estrogen may be considered after a risks-and-benefits discussion, with gynecologist-oncologist shared decision-making for aromatase-inhibitor use. 1, 3
FDA consumer guidance says systemic hormone therapy should not be used with unexplained vaginal bleeding, certain breast or uterine cancers, prior blood clot, stroke or heart attack, bleeding disorders, liver disease, or a serious hormone-medicine allergy. 4
Age, timing, symptoms, and history shape the decision
| Category | What it means | Common routes | Worth knowing |
|---|---|---|---|
| Estrogen-only treatment | Systemic estrogen without a progestogen | Patch, gel, spray, pill | Usually after hysterectomy; without progestogen, systemic estrogen raises endometrial-cancer risk. 5 |
| Estrogen plus progestogen | Systemic estrogen with endometrial protection | Combined product or separate estrogen and progestogen | Usually used when a uterus is present 5 |
| Systemic route | Hormone reaches the bloodstream and tissues throughout the body | Pill, patch, gel, spray | Used for symptoms such as hot flashes and night sweats; route affects the risk discussion 2, 5 |
| Local vaginal route | Low-dose estrogen is delivered to vaginal tissue | Cream, ring, tablet or insert | Used for genitourinary symptoms; it follows a different exposure and safety discussion from systemic therapy 5 |
A note on "bioidentical" and compounded hormones
Custom-compounded hormones are prepared from a patient-specific prescription and are not FDA-approved products. The Menopause Society says compounded bioidentical hormone therapy presents safety concerns and recommends government-approved products for almost all women. A clinician can explain approved formulations before any compounded option is considered. 2
The words "natural" and "bioidentical" do not establish that a compounded product is safer or more effective. Product approval, evidence, formulation, and monitoring matter more than the marketing label. 2
Ask which FDA-approved formulation addresses the symptom being treated and why a particular route was chosen. A custom product should not be presented as safer simply because it is compounded. 2
How to get evaluated without being dismissed
A solid evaluation starts with symptoms, cycle history, personal and family history, goals, and the risks and benefits of the available options. Testing is useful when the history suggests another condition or the result would change care; a single hormone result does not decide systemic hormone-therapy suitability.
Your next three steps
- Write down the symptoms that most affect sleep, comfort, or daily life.
- List your uterus status, bleeding pattern, medicines, and personal and family history of cancer, clots, stroke, heart attack, and liver disease.
- Ask a licensed clinician which treatment type and route, if any, fits that history and what follow-up the specific product requires.
Explore your hormone therapy options
- Online evaluation by a licensed clinician
- Treatment based on your health and goals
- Clear pricing before you commit
From price shown is the 6-month plan rate. Prices may vary.
Frequently asked questions
Was this helpful?
Keep reading
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Women's Health
Sources
- FDA. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." February 12, 2026. fda.gov
- The Menopause Society. ‘2022 Hormone Therapy Position Statement’ release. Accessed September 15, 2026. menopause.org
- ACOG. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer." December 2021. acog.org
- FDA. ‘Menopause: Medicines to Help You.’ Current page accessed September 15, 2026. fda.gov
- ACOG. ‘Hormone Therapy for Menopause.’ Current FAQ accessed September 15, 2026. acog.org